stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Revenue growth
Zymeworks Inc.'s revenue growth over the twelve months to 30 June 2026 was −69.8%, down 108.6 percentage points from fiscal 2025 (38.9%). Over the past ten years it has ranged from −81.6% (fiscal 2023) to 1,446.0% (fiscal 2022); the current reading is higher than 82% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 38.9% | 38.49 |
| FY2024 | 0.38% | 81.95 |
| FY2023 | −81.6% | (1,527.60) |
| FY2022 | 1,446.0% | 1,477.53 |
| FY2021 | −31.5% | (63.34) |
| FY2020 | 31.8% | 76.12 |
| FY2019 | −44.3% | (46.71) |
| FY2018 | 2.43% | (367.75) |
| FY2017 | 370.2% | 356.22 |
| FY2016 | 14.0% | 26.21 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | −90.6% | 0.54 |
| Mar 2026 | −91.1% | 0.78 |
| Dec 2025 | −91.9% | (164.49) |
| Sep 2025 | 72.6% | (80.62) |
| 38 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SEPN Septerna, Inc. compare | 13,520.1% |
| BHVN Biohaven Ltd. compare | 425.2% |
| VCEL Vericel Corporation compare | 25.3% |
| AUPH Aurinia Pharmaceuticals Inc compare | 21.0% |
| IMNM Immunome, Inc. compare | 16.7% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −52.2% |
| ZYME Zymeworks Inc. | −69.8% |
| COAG Hemab Therapeutics Holdings, Inc. compare | — |
| VERA Vera Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement